Home›Anti Fungal Agents That Are Cyp3a4 Substrates›Anti Fungal Agents That Are Cyp3a4 Substrates + Enasidenib Mesylate

Does Anti Fungal Agents That Are Cyp3a4 Substrates Interact with Enasidenib Mesylate?

Anti Fungal Agents That Are Cyp3a4 Substrates and Enasidenib Mesylate have a major drug interaction according to U.S. FDA drug labeling data. Do not administer enasidenib with anti-fungal agents that are CYP3A substrates due to expected loss of antifungal efficacy. The mechanism involves cyp3a induction leading to decreased antifungal exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Anti Fungal Agents That Are Cyp3a4 Substrates and Enasidenib Mesylate occurs because cyp3a induction leading to decreased antifungal exposure. Clinically, this means do not administer enasidenib with anti-fungal agents that are cyp3a substrates due to expected loss of antifungal efficacy. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Anti Fungal Agents That Are Cyp3a4 Substrates and your doctor is considering prescribing Enasidenib Mesylate (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Anti Fungal Agents That Are Cyp3a4 Substrates+💊 Enasidenib Mesylate(Idhifa)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
—
Source
NLP:enasidenib mesylate

What this means in plain English

Do not administer enasidenib with anti-fungal agents that are CYP3A substrates due to expected loss of antifungal efficacy.

What the FDA label says

"CYP3A induction leading to decreased antifungal exposure"

📖 Source: NLP:enasidenib mesylate

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Anti Fungal Agents That Are Cyp3a4 Substrates and Enasidenib Mesylate against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.